Danyelza receives FDA approval for treatment of neuroblastoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has granted accelerated approval to Danyelza (naxitamab-gqgk) 40mg/10ml in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In the days leading up to the 2021 American Society of Clinical Oncology annual meeting, The Cancer Letter published a piece focused on Axel Grothey’s unethical sexual relationships with women he mentored while at Mayo Clinic. While this news was met by some as shocking, science tells us it is anything but.

Login